---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Lifestyle and dietary interventions"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Lifestyle and dietary interventions. Topics: Lifestyle recommendation for all adults: 2025 AHA/ACC guideline, Expected blood pressure reductions by intervention: 2025 AHA/ACC guideline, Potassium-based salt substitutes: 2025 AHA/ACC guideline, Sodium target and lifestyle intervention in resistant hypertension: 2024 ESC guideline, and 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/lifestyle-and-dietary-interventions"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Lifestyle and dietary interventions

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Lifestyle and Dietary Interventions

<a id="topic-2.2.2.1.1-1"></a>

### Lifestyle recommendation for all adults: 2025 AHA/ACC guideline

> “For all adults, lifestyle changes, including maintaining or achieving a healthy weight, following a heart-healthy eating pattern (such as DASH [Dietary Approaches to Stop Hypertension]), reducing sodium intake, increasing dietary potassium intake, adopting a moderate physical activity program, managing stress, and reducing or eliminating alcohol intake are strongly recommended to prevent or treat elevated blood pressure and hypertension.”
> “Once patients have been diagnosed with hypertension, specific lifestyle and nonpharmacological strategies can lower BP, slow progression of BP elevation, reduce the amount of medication needed to control BP, and prevent CVD events and mortality.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.1-2"></a>

### Expected blood pressure reductions by intervention: 2025 AHA/ACC guideline

> “Aim for sustained ≥5% reduction in body weight or ≥3 kg/m2 reduction in BMI; expect about 1 mm Hg reduction for every 1-kg reduction in body weight”
> “Reduction in BP with the DASH eating plan varies across trials, from 1 to 13 mm Hg for SBP and from 1 to 10 mm Hg for DBP.”
> “On average, low-sodium (≤1500-2300 mg/d) versus high-sodium (≥4500 mg/d) diets safely result in BP reductions of approximately 3/2 mm Hg (systolic/diastolic) in normotensive and 7/3 mm Hg in hypertensive individuals.”
> “Aerobic exercise reduces SBP on average by 4 to 7/3 to 4 mm Hg, with a slightly larger effect in patients with versus without hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.1-3"></a>

### Potassium-based salt substitutes: 2025 AHA/ACC guideline

> “COR 2a: In adults with or without hypertension, potassium-based salt substitutes can be useful to prevent or treat elevated BP and hypertension, particularly for patients in whom salt intake is related mostly to food preparation or flavoring at home, except in the presence of CKD or use of drugs that reduce potassium excretion where additional monitoring is probably indicated.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.1-4"></a>

### Sodium target and lifestyle intervention in resistant hypertension: 2024 ESC guideline

> “It is recommended to restrict total dietary sodium intake to approximately 2 g/day or less (equivalent to approximately 5 g or about a teaspoon of salt per day).”
> “The Treating Resistant Hypertension Using Lifestyle Modification to Promote Health (TRIUMPH) trial demonstrated significant clinic and ambulatory BP reductions in patients with resistant hypertension participating in a 4-month lifestyle intervention comprising diet and exercise interventions delivered within a cardiac rehabilitation programme.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.1-5"></a>

### Diet and exercise program in resistant hypertension: TRIUMPH randomized trial

> “One hundred forty patients with RH (mean age 63 years; 48% female; 59% Black; 31% with diabetes; 21% with chronic kidney disease) were randomly assigned to a 4-month program of lifestyle modification (C-LIFE) including dietary counseling, behavioral weight management, and exercise; or a single counseling session providing standardized education and physician advice (SEPA).”
> “Between-group comparisons revealed that the reduction in clinic SBP was greater in C-LIFE (−12.5 [95% CI: −14.9, −10.2] mm Hg) compared with SEPA”
> “24-hour ambulatory SBP also was reduced in C-LIFE (−7.0 [95% CI: −8.5, −4.0] mm Hg), with no change in SEPA (−0.3 [95% CI: −4.0, 3.4] mm Hg) (P = .001).”

Source: [Blumenthal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8511053/)

<a id="topic-2.2.2.1.1-6"></a>

### Dietary sodium restriction in resistant hypertension: crossover trial

> “Twelve subjects with resistant hypertension entered into a randomized, cross-over evaluation of low (50 mmol/24-hr × 7 days) and high sodium diets (250 mmol/24-hr × 7 days) separated by a 2-week washout period.”
> “Low- compared to high-salt diet decreased office systolic and diastolic blood pressure by 22.7 and 9.1 mm Hg, respectively.”

Source: [Pimenta et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2771382/)

<a id="topic-2.2.2.1.1-7"></a>

### Sodium reduction combined with the DASH diet: DASH-Sodium trial

> “A total of 412 participants were randomly assigned to eat either a control diet typical of intake in the United States or the DASH diet.”
> “As compared with the control diet with a high sodium level, the DASH diet with a low sodium level led to a mean systolic blood pressure that was 7.1 mm Hg lower in participants without hypertension, and 11.5 mm Hg lower in participants with hypertension.”

Source: [Sacks et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11136953/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
